Compliance · State rules

Office-use compounding in Ohio

Narrow statutory carve-out; legally contested

USPeptideRx EditorialLast reviewed: August 28, 2026

Ohio statute contains a narrow human office-use carve-out gated on three cumulative conditions, while a Board rule independently commands compliance with 21 U.S.C. § 353a. The two point in opposite directions, so Ohio should be treated as contested rather than as an office-use state.

The governing rule

Ohio’s office-use position is set by R.C. 4729.01(C)(5); OAC 4729:7-2-03(E). The text below is quoted verbatim; everything outside a quote block is our summary of it, and the two are kept visually separate on purpose.

R.C. 4729.01(C)(5) — definition of "compounding"

(5) Pursuant to a request made by a licensed health professional authorized to prescribe drugs for a drug that is to be used by the professional for the purpose of direct administration to patients in the course of the professional’s practice, if all of the following apply: (a) At the time the request is made, the drug is not commercially available regardless of the reason that the drug is not available, including the absence of a manufacturer for the drug or the lack of a readily available supply of the drug from a manufacturer. (b) A limited quantity of the drug is compounded and provided to the professional. (c) The drug is compounded and provided to the professional as an occasional exception to the normal practice of dispensing drugs pursuant to patient-specific prescriptions.

OAC 4729:7-2-03(E) — effective March 7, 2024

Comply with Title 21 U.S. Code section 353a (11/27/2013).

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

Three cumulative gatesHigh confidence: Not commercially available, AND limited quantity, AND an occasional exception to normal patient-specific dispensing. A recurring, volume-based office-stock programme fails the third gate on its face; any product with a commercial equivalent fails the first.
Administer-onlyHigh confidence: Explicit — "for the purpose of direct administration to patients".
The conflictLow confidence: The statute carves out narrow human office use; the rule commands § 353a compliance, which requires a patient-specific prescription. No Board guidance reconciling the two was found.Confidence in the existence of the conflict is high. Confidence in how the Board would resolve it is low — which is precisely why Ohio is not represented here as permitting office use.
Veterinary channelHigh confidence: OAC 4729:7-2-05 (eff. July 1, 2021) is the only fully built-out office-use pathway, and it applies only to animal use. Non-patient-specific sale is allowed where the drug is not commercially available and for an emergency, an unanticipated procedure where delay would harm outcome, or diagnostic purposes.
Occasional-sale pathwayHigh confidence: Does not cover human compounded office stock. OAC 4729:5-3-09 (eff. May 1, 2025) defines "occasional sale" as a wholesale sale of a commercially manufactured dangerous drug — the word "compound" does not appear in the rule.
Prescriber licensure (the med-spa lever)High confidence: Board guidance updated 1/13/2025 states that "in general, the exemptions to Ohio’s TDDD licensure requirements do not apply if the prescriber practice is engaged in drug compounding," and warns that "preparation of such medications in advance of administration requires licensure and compliance with the Board’s compounding rules."One of the five carved-out lower-risk activities is possession of compounded preparations supplied by an Ohio-licensed 503B outsourcing facility — the Board’s own document routes prescriber-held office stock toward 503B.
Board reportingHigh confidence: Within 72 hours of discovery: any product quality issue attributed to a compounded drug the pharmacy dispensed (mix-up or mislabelling, contamination, or significant chemical or physical deterioration within the assigned BUD), required regardless of whether the compounded drug is sold. Also within 72 hours: any FDA warning letter, injunction, or decree issued to the pharmacy.
USP standards updateHigh confidence: OAC 4729:7-1-01 was updated in 2026 to require the newest USP <797> (adopted Feb. 1, 2026) and USP <795> (adopted Nov. 1, 2023). A Board resolution delays enforcement to February 28, 2027, and licensees are prohibited from using the newer BUDs unless they can demonstrate full compliance with the new chapters.The two dates reported by the Board are not in conflict, and the apparent conflict is an artefact of reading one of them as the only effective date. codes.ohio.gov carries rule 4729:7-1-01 with an effective date of June 1, 2026 and prior effective dates of March 31, 2021 and February 28, 2026: the February 2026 version is the one that introduced the current USP references, and June 1, 2026 is a later amendment on top of it. The February 28, 2027 enforcement delay is a separate Board resolution and is unaffected by either date.

Ohio at a glance

Ohio office-use compounding summary, reviewed 2026-08-28
Human office use	Narrow statutory carve-out; contested
Sterile preparations	Both, subject to the same gates
Quantity cap	"Limited quantity" — no percentage
Mandatory label legend	None required
Board reporting	72-hour product quality + FDA letters
Last change	USP refs 2026; occasional sale May 2025
Governing rule	R.C. 4729.01(C)(5); OAC 4729:7-2-03(E)

Receiving 503B office stock in Ohio

Ohio is the clearest state in this family for the proposition that the receiving practice has its own licensing problem — and the Board’s own guidance names the 503B route as the clean way to hold compounded stock.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Ohio asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inMedium confidence: An Ohio credential. The Board’s prescriber guidance describes the carved-out activity as possession of compounded preparations supplied by an "Ohio-licensed 503B outsourcing facility", so the facility is expected to hold an Ohio licence rather than FDA registration on its own. The exact licence category was not read from a primary source in this review.
Does your practice need a permit?High confidence: Yes — a terminal distributor of dangerous drugs (TDDD) licence. Board guidance updated 13 January 2025 states that "in general, the exemptions to Ohio’s TDDD licensure requirements do not apply if the prescriber practice is engaged in drug compounding," and warns that "preparation of such medications in advance of administration requires licensure and compliance with the Board’s compounding rules."The guidance carves out five lower-risk activities that do not themselves trigger compounding licensure, and the fourth is possession of compounded preparations supplied by an Ohio-licensed outsourcing facility. The document uses med-spa examples directly.
Administer vs dispenseHigh confidence: The statutory carve-out on the 503A side is administer-only by its own terms — R.C. 4729.01(C)(5) reaches a drug "to be used by the professional for the purpose of direct administration to patients". On the 503B side the Board frames its carve-out as possession of the facility’s product for administration, and every lower-risk activity it lists is administration-side.
Scheduled (controlled) stockNot verified: Not separately researched for Ohio in this review. Scheduled stock raises the TDDD question in a different posture; confirm with the Board before holding any.

How to check a facility’s credential before you order is set out in how to place an office-use order.

The federal layer still applies

Whatever Ohio law allows, federal law applies on top of it and is not satisfied by state permission. 21 U.S.C. § 353a conditions the federal compounding exemptions on a drug being compounded for an identified individual patient on receipt of a valid prescription order. A state rule cannot create a federal safe harbour, and several state rules say so in their own text. The separate federal pathway for non-patient-specific office stock is the 503B outsourcing facility — the differences are set out in 503A vs 503B.

For how Ohio compares with the other states reviewed, see the state-by-state comparison.

What this page does not establish

R.C. 4729.01(C)(5) and OAC 4729:7-2-03(E) pull against each other, and we found no Board guidance reconciling them. How that conflict resolves is unknown, and it is beyond what this page can tell you — treat it as open, and put it to the Board or to counsel before relying on either.
Which USP <797> text the Board’s February 2026 version date points to — a USP revision, or a snapshot of a USP-NF edition — is unresolved. USP’s own public page shows <797> official as of November 1, 2023, so this page reads Ohio’s date as the date the state incorporated the chapter, never as a date USP revised it. If your position turns on which text applies, confirm it with the Board.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.